Prostate specific antigen (PSA) has emerged as a useful tumor marker in oncology and PSA-based screening is widely used despite a relative lack of both specificity, leading to overdiagnosis and treatment of early stage prostate cancer, and sensitivity, leading to prostate cancer not being detected early enough [1–5]. This evidence concerns the gene KLK3 and prostate carcinoma.